MK-677 Dosing in Young Adults: Study Arms Are Not a Regimen

A Number in a Paper Has a Job Description

The legacy page presented a “typical” range, starting instruction, nighttime rule, cycle length, laboratory cadence, and stop thresholds. Those were not FDA labeling and were not the conclusions of a young-adult dose-finding trial.

FDA's multidisciplinary ibutamoren review team summarized the limitation:

“Most of the available clinical data have limitations such as lack of demonstration of clinically meaningful therapeutic effects, small study sizes, and short study durations.”

The statement appears in FDA's 2024 evaluation of ibutamoren mesylate for the 503A Bulks List. It qualifies the overall evidence; it does not recommend a dose or imply that every study had the same limitation.

The Study-Arm Replay

Study doses are reported here so readers can understand the evidence. They are not instructions to reproduce the experiments.

What the Nine-Person Young-Men Study Actually Established

Copinschi and colleagues used a randomized, double-blind, three-period crossover design. Nine healthy young men received placebo and two MK-677 study arms at bedtime for seven consecutive days. Investigators sampled GH and cortisol intensively and measured IGF-1 and IGFBP-3 (PMID 8768828; DOI 10.1210/jcem.81.8.8768828).

The study found hormone-profile changes. It did not compare:

• starting strategies;
• titration versus no titration;
• morning versus evening clinical outcomes;
• cycling versus continuous use;
• muscle strength, injury recovery, or quality of life;
• long-term glucose outcomes;
• fertility or pregnancy outcomes;
• discontinuation methods; or
• products from different sources.

Calling one arm “standard dosing” assigns the study a conclusion it did not make.

Why the Eight-Week Obesity Trial Does Not Fill the Gap

Svensson and colleagues randomized 24 otherwise healthy males ages 18–50 with obesity to one active arm or placebo for eight weeks (PMID 9467542; DOI 10.1210/jcem.83.2.4539). GH and IGF-1 increased, fat-free mass increased, total and visceral fat did not significantly change, and an oral glucose tolerance test showed impaired glucose homeostasis at weeks two and eight.

That is useful efficacy-and-safety evidence for a defined population and experimental arm. It still does not identify the lowest effective dose, an age-18-to-29 target, a better timing schedule, or a favorable risk-benefit balance for a clinical use.

Five Missing Inputs Defeat the “Dose Calculator”

A clinical dosing recommendation ordinarily needs:

1. a defined indication and target outcome;
2. a characterized product and formulation;
3. exposure-response and dose-response evidence;
4. a safety margin in the intended population; and
5. a monitoring and adjustment rule validated against outcomes.

Ibutamoren has experimental exposures, but not that complete chain for healthy young adults. Multiplying a trial arm by body weight, reducing it for caution, or dividing it into a “cycle” does not create the missing validation.

Timing and Food Are Separate Questions

Bedtime administration in one study does not prove bedtime is safer or more effective. FDA's review also found only limited human PK description, with no detailed food-effect evidence from which to establish a meal interval.

The food and supplement interaction audit examines that question directly. The young-adult safety page separates observed adverse findings from unmeasured outcomes, and the adolescent evidence review explains why pediatric research arms do not cross developmental boundaries.

The Responsible Bottom Line

Human studies document experimental ibutamoren doses; none creates an FDA-approved or evidence-validated young-adult regimen. This page cannot responsibly prescribe a starting dose, target dose, cycle, titration, meal interval, laboratory schedule, or taper.

Medical review of this revision is pending. FDA, investigators, institutions, journals, sponsors, and study authors do not endorse ibutamoren, HealthRX.com, or this page.